Insider Selling: Sight Sciences (NASDAQ:SGHT) EVP Sells $10,615.30 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) EVP Brenton Taylor sold 2,869 shares of the stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $3.70, for a total value of $10,615.30. Following the completion of the sale, the executive vice president directly owned 267,807 shares of the company’s stock, valued at $990,885.90. The trade was a 1.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Brenton Taylor also recently made the following trade(s):

• On Tuesday, January 6th, Brenton Taylor sold 619 shares of Sight Sciences stock. The shares were sold at an average price of $7.48, for a total transaction of $4,630.12.

Sight Sciences Price Performance

SGHT stock opened at $3.52 on Monday. The company has a market cap of $190.12 million, a price-to-earnings ratio of -4.69 and a beta of 2.50. The company has a fifty day moving average price of $4.82 and a 200 day moving average price of $5.76. The company has a debt-to-equity ratio of 0.63, a current ratio of 10.22 and a quick ratio of 9.52. Sight Sciences, Inc. has a 12 month low of $2.03 and a 12 month high of $9.24.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings data on Wednesday, March 4th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.07. The company had revenue of $20.39 million for the quarter, compared to the consensus estimate of $20.35 million. Sight Sciences had a negative net margin of 49.67% and a negative return on equity of 55.72%. Sell-side analysts expect that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Piper Sandler set a $9.00 price target on Sight Sciences in a research report on Monday, January 5th. UBS Group decreased their price objective on Sight Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, March 6th. Stifel Nicolaus lifted their target price on Sight Sciences from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Raymond James Financial set a $9.00 target price on Sight Sciences in a report on Monday, January 5th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Sight Sciences in a research note on Monday, December 29th. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.31.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Alliancebernstein L.P. lifted its position in Sight Sciences by 5.5% in the third quarter. Alliancebernstein L.P. now owns 34,380 shares of the company’s stock valued at $118,000 after purchasing an additional 1,800 shares during the period. Deutsche Bank AG increased its position in Sight Sciences by 9.8% during the 4th quarter. Deutsche Bank AG now owns 27,355 shares of the company’s stock worth $217,000 after purchasing an additional 2,439 shares during the period. Tower Research Capital LLC TRC increased its position in Sight Sciences by 32.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock worth $48,000 after purchasing an additional 2,875 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Sight Sciences by 1.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 303,634 shares of the company’s stock worth $1,045,000 after buying an additional 3,051 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its stake in shares of Sight Sciences by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock worth $26,000 after buying an additional 3,785 shares in the last quarter. 55.51% of the stock is owned by hedge funds and other institutional investors.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.